AMENDMENTS TO THE CLAIMS

1. (original) A peptide which comprises any one of the amino acid sequences selected from a group consisting of:
Arg Tyr Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 2),
Arg Tyr Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 3),
Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 4),
Ala Tyr Leu Pro Ala Val Pro Ser Leu (SEQ ID NO: 5), and
Asn Tyr Met Asn Leu Gly Ala Thr Leu (SEQ ID NO: 6).

2. (original) The peptide according to claim 1, which consists of any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6.

3. (original) A peptide which comprises an altered amino acid sequence wherein an alteration of an amino acid residue is comprised in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6, and which has an activity to induce a CTL in an HLA-A24-restricted manner, except for a peptide comprising the amino acid of SEQ ID NO: 7.

4. (original) The peptide according to claim 3, which comprises an altered amino acid sequence wherein leucine at position 9 in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 5, and 6 is substituted by phenylalanine, tryptophan, isoleucine, or methionine.

5. (original) The peptide according to claim 3, which comprises an altered amino acid sequence wherein phenylalanine at position 9 in the amino acid sequence of SEQ ID NO: 4 is substituted by tryptophan, leucine, isoleucine, or methionine.

6. (original) The peptide according to claim 3, which comprises an altered amino acid sequence wherein cysteine at position 5 in the amino acid sequence of SEQ ID NO: 4 is substituted by alanine, serine, or α-aminobutyric acid (SEQ ID NO: 66, 67, or 68).

7. canceled.

8. (currently amended) A polynucleotide which encodes the peptide according to any one of claims 1 to ~~7~~6.

9. canceled

10. (currently amended) An expression vector which ~~contains~~ comprises the polynucleotide of claim 8 ~~or 9~~.

11. (currently amended) A cell which comprises ~~the expression vector of claim 10~~an expression vector comprising a polynucleotide encoding the peptide of claim 1 or claim 3.

12. (currently amended) A process for preparing a peptide ~~according to any one of claims 1 to 7~~ which comprises any one of

the amino acid sequences selected from a group consisting of: Arg Tyr Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 2), Arg Tyr Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 3), Arg Tyr Pro Ser Cys Gln Lys Lys Phe (SEQ ID NO: 4), Ala Tyr Leu Pro Ala Val Pro Ser Leu (SEQ ID NO: 5), and Asn Tyr Met Asn Leu Gly Ala Thr Leu (SEQ ID NO: 6), or which comprises an altered amino acid sequence wherein an alteration of an amino acid residue is comprised in any one of the amino acid sequences selected from a group consisting of SEQ ID NOs: 2, 3, 4, 5, and 6, and which has an activity to induce a CTL in an HLA-A24-restricted manner, except for a peptide comprising the amino acid of SEQ ID NO: 7, which comprises culturing the cell according to claim 11 in a condition operable for the expression of peptides.

13. (currently amended) An antibody which specifically binds to the peptide according to ~~any one of claims 1 to 7~~claim 1.

14. (currently amended) An antigen-presenting cell on which a complex between a cancer antigen peptide derived from the peptide according to ~~any one of claims 1 to 7~~claim 1 or claim 3 and an HLA-A24 antigen is presented.

15. (original) The antigen-presenting cell according to claim 14, on which a complex between a cancer antigen peptide consisting of any one of the amino acid sequences selected from

the group consisting of SEQ ID NOs: 2 to 6 and 66 to 68 and an HLA-A24 antigen is presented.

16. (currently amended) A CTL which recognizes a complex between a cancer antigen peptide derived from the peptide according to ~~any one of claims 1 to 7~~ claim 1 or claim 3 and an HLA-A24 antigen.

17. (original) The CTL according to claim 16, which recognizes a complex between a cancer antigen peptide consisting of any one of the amino acid sequences selected from the group consisting of SEQ ID NOs: 2 to 6 and 66 to 68 and an HLA-A24 antigen.

18. (currently amended) A pharmaceutical composition which comprises the peptide according to ~~any one of claims 1 to 7~~claim 1 or claim 3~~, the polynucleotide according to claim 8 or 9, the expression vector according to claim 10, the cell according to claim 11, the antigen-presenting cell according to claim 14 or 15, or the CTL according to claim 16 or 17,~~ together with a pharmaceutically acceptable carrier.

19. (currently amended) A cancer vaccine which comprises as an effective ingredient the peptide according to ~~any one of claims 1 to 7~~claim 1~~, the polynucleotide according to claim 8 or 9, the expression vector according to claim 10, the cell according to claim 11, the antigen-presenting cell according to~~

~~claim 14 or 15, or the CTL according to claim 16 or 17~~.

20. canceled.

21. (currently amended) A method for treatment or prevention of a cancer, which comprises administering a therapeutically or prophylactically effective amount of the peptide according ~~to any one of claims 1 to 7, the polynucleotide according to claim 8 or 9, the expression vector according to claim 10, the cell according to claim 11, the antigen-presenting cell according to claim 14 or 15, or the CTL according to claim 16 or 17,~~ claim 1 or claim 3 to a cancer patient in need who is positive for an HLA-A24, and positive for WT1.

22. (original) A pharmaceutical composition which comprises any one of the substances selected from the group consisting of:
a) a peptide which comprises the sequence of Arg Val Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 7),
b) a polynucleotide which encodes the peptide as shown above a),
c) an expression vector which comprises the polynucleotide as shown above b),
d) a cell which comprises the expression vector as shown above c),
e) an antigen-presenting cell on which a complex between a cancer antigen peptide derived from the peptide as shown above a) and an HLA-A24 antigen is presented, and
f) a CTL which recognizes a complex between a cancer antigen

peptide derived from the peptide as shown above a) and an HLA-A24 antigen,
together with a pharmaceutically acceptable carrier.

23. canceled.

24. canceled.

25. (original) A method for treatment or prevention of a cancer, which comprises administering a therapeutically or prophylactically effective amount of any one of the substances selected from the group consisting of:
a) a peptide which comprises the sequence of Arg Val Pro Gly Val Ala Pro Thr Leu (SEQ ID NO: 7),
b) a polynucleotide which encodes the peptide as shown above a),
c) an expression vector which comprises the polynucleotide as shown above b),
d) a cell which comprises the expression vector as shown above c),
e) an antigen-presenting cell on which a complex between a cancer antigen peptide derived from the peptide as shown above a) and an HLA-A24 antigen is presented, and
f) a CTL which recognizes a complex between a cancer antigen peptide derived from the peptide as shown above a) and an HLA-A24 antigen,
to a cancer patient in need who is positive for an HLA-A24, and positive for WT1

26. (new) A pharmaceutical composition which comprises the polynucleotide encoding a peptide according to claim 1 or claim 3 and a pharmaceutically acceptable carrier.

27. (new) A pharmaceutical composition which comprises an expression vector encoding a peptide according to claim 1 or claim 3 and a pharmaceutically acceptable carrier.

28. (new) A pharmaceutical composition which comprises the cell according to claim 11 and a pharmaceutically acceptable carrier.

29. (new) A pharmaceutical composition which comprises the antigen-presenting cell according to claim 14 and a pharmaceutically acceptable carrier.

30. (new) A pharmaceutical composition which comprises the CTL according to claim 16 and a pharmaceutically acceptable carrier.

31. (new) A cancer vaccine which comprises the expression vector according to claim 10.

32. (new) A cancer vaccine which comprises the antigen-presenting cell according to claim 14.

33. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the expression vector according to claim 10 to a cancer patient who is positive for HLA-A24 and positive for WT1.

34. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the cell according to claim 11 to a cancer patient who is positive for HLA-A24 and positive for WT1.

35. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the antigen-presenting cell according to claim 14 to a cancer patient who is positive for HLA-A24 and positive for WT1.

36. (new) A method for treating or preventing a cancer, which comprises administering a therapeutically or prophylactically effective amount of the CTL according to claim 16 to a cancer patient who is positive for HLA-A24 and positive for WT1.